Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Assertio Therapeutics ( (ASRT) ) has shared an announcement.
Assertio Holdings announced key leadership changes, appointing Paul Schwichtenberg as Chief Transformation Officer and Mary Pietryga as Chief Commercial Officer, effective December 2024. These appointments, along with Mark Reisenauer’s addition to the Board, are aimed at driving new revenue strategies and market growth, positioning Assertio for continued success.
More about Assertio Therapeutics
Assertio is a commercial pharmaceutical company with comprehensive capabilities, offering differentiated products to patients. It builds its commercial portfolio through acquisition or licensing of approved products, utilizing both a sales force and non-personal promotion model, and focuses on market access, payor contracting, and distribution.
YTD Price Performance: -12.15%
Average Trading Volume: 713,559
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $89.75M
For a thorough assessment of ASRT stock, go to TipRanks’ Stock Analysis page.
